Voximetry, Inc. has been accepted into the spring 2021 SBIR Advance program sponsored by the Center for Technology Commercialization (CTC), part of the Wisconsin Economic Development Corporation (WEDC). The program provides state match funding, training, and other resources to Wisconsin businesses to advance the commercialization of Small Business Innovation Research (SBIR) funded technology and expedite economic and job creation impact in Wisconsin. 

This competitive grant supplements the $1.8M Phase II SBIR grant awarded to Voximetry by the National Cancer Institute at the National Institutes of Health.

“Voximetry is extremely grateful for the generous support awarded to us by the CTC.  The funding will allow us to accelerate the commercial launch of our flagship product, Torch,” said Dr. Sue Wallace, CEO of Voximetry.  “Most important, the guidance and feedback from the CTC mentors will mature our business plan and better position us for success.”

Voximetry continues its momentum with hiring of Chief Executive Officer Dr. Sue Wallace. 

MADISON, Wis.-- Voximetry Inc., a Madison, Wisconsin-based Healthtech software company with unique technology for personalized Radiopharmaceutical Therapy (RPT) planning, has announced the permanent appointment of Susan L. Wallace, PhD as Chief Executive Officer.

Voximetry’s Torch™ software platform implements proprietary Monte Carlo algorithms on high-speed Graphic Processing Units (GPUs). This voxel-based dosimetry enables physicians to effectively treat metastatic disease without exceeding toxicity thresholds of critical organs.

Voximetry’s Chairman, Chief Science Officer & Co-founder, Dr. Bryan Bednarz, stated, “With the appointment of Dr. Wallace, we have locked in key leadership to accelerate our time to commercial launch. Sue’s extensive global experience leading radiation-based medical imaging and therapy businesses provides the Company with important insight into market dynamics and alliances. We are confident this addition will not only accelerate our time to market but also improve the market adoption of dosimetry and our Torch offerings.”

Dr. Joe Grudzinski, Voximetry’s Chief Innovation Officer & Co-founder, added, “Our unique algorithms developed at the University of Wisconsin represent the new frontier of therapy planning for RPT. By adapting them to GPUs and providing widespread commercial access, we’re providing important fuel to ignite and feed the $5B market for RPT that has been projected over the next 5 years. We’re excited to have a new leader who understands the potential from day one.”

Dr. Wallace has spent her entire career advancing innovative radiation science technologies. Sue received her Bachelor of Science degree in Chemistry from the University of Wisconsin in Milwaukee. She went on to earn a Master of Science degree in Nuclear Chemistry and a Doctorate degree in PET Radiopharmaceutical Chemistry from Washington University in St. Louis. In addition, she was trained in Six Sigma methodology during her tenure at GE Healthcare and is an experienced Six Sigma Master Black Belt. Sue has held both commercial and operational senior leadership positions in large global Healthtech companies including GE, Philips, Cardinal Health and Accuray. She also spent many years working with early stage and pre-revenue small companies to accelerate product development and prepare for commercial launch. 

About Voximetry Inc.: Based in Madison, Wisconsin, Voximetry is a is an early-stage Healthtech company specializing in commercialization of complex algorithms on high speed Graphic Processing Units (GPUs). Currently focused on radiation transport science, Voximetry is advancing patient-specific treatment planning in advanced stage cancer patients.   Voximetry leverages intellectual property developed at the University of Wisconsin - Madison, which has a rich history of fostering successful biotechnology companies.  Torch has not yet been submitted to FDA for review of its Indications for Use and is therefore NOT suitable for clinical use.

According to the scientific needs of clinical trials led by the National Clinical Trials Network (NCTN), groups receive support from the IROC group and others. To support current and future trials, IROC plans to evaluate the potential of dosimetry in alpha- and beta-emitting Radiopharmaceutical Therapy (RPT) clinical trials. 

Voximetry's voxel-based dosimetric software, Torch™, is included in the evaluation plans.

Voximetry is a company focused on implementing complex software algorithms on high speed Graphic Processing Units (GPUs) to assist in cancer care planning. 

IROC is a center for the evaluation of data produced by clinical trials funded by the National Cancer Institute, as part of the NCTN to provide integrated radiation oncology and diagnostic imaging quality control programs and to assure high quality data for clinical trials designed to improve the clinical outcomes for cancer patients worldwide. 

IROC is the first industry group to install and train on Voximetry software.

Voximetry Awarded $1.8 Million Grant from National Cancer Institute to Advance the Development of its Radiopharmaceutical Therapy Dosimetry Software

MADISON, Wis.--Voximetry Inc., an early stage medical software company with unique technology for personalized Radiopharmaceutical Therapy (RPT) planning, has been awarded a substantial grant from the U.S. National Institutes of Health (NIH)’s National Cancer Institute (NCI) to advance development of its proprietary software for RPT dosimetry.

According to Voximetry CEO, Dr. Sue Wallace, “We are grateful to the NCI. This grant will accelerate our work to provide a tool that enables clinicians to personalize care for individual patients and thereby achieve better outcomes, including better quality of life after treatment.”

The field of RPT is expanding rapidly in the U.S. with procedure volumes increasing in multiple specialty areas including Nuclear Medicine, Radiation Oncology and Interventional Radiology departments. A March 2020 review by top experts published in the Lancet indicates the field of RPT will exceed $5B in the next 5 years. In addition to currently approved treatments, at least 100 clinical trials using new RPT agents are currently underway, focused primarily on Prostate, Lymphoma, Thyroid, Liver, and Neuroendocrine tumors.

“Our TORCH software will provide the information needed to help physicians prescribe the right number of therapy cycles and the right therapy dose per cycle,” said Dr. Joe Grudzinski, Chief Innovation Officer at Voximetry. “After treatment, our users will know how much therapeutic dose was delivered to the targeted disease sites, as well as to healthy tissue and critical organs. Torch information can help doctors prescribe just enough dose to treat the disease and still protect important organs like the kidneys, lungs, or salivary glands.”

The $1.8 Million Phase II Small Business Innovation Research (SBIR) grant from the NCI will fund commercial development of Voximetry’s Torch software and demonstration of safety and efficacy.

As part of this grant, University of WI collaborators will use Voximetry’s software for retrospective assessment of RPT treatments. 

About Voximetry:  Based in Madison, Wisconsin, Voximetry is a is an early stage healthcare technology company specializing in commercialization of complex algorithms on high speed Graphic Processing Units (GPUs). Currently focused on radiation transport science and voxel-level dosimetry, Voximetry is pioneering patient-specific treatment planning in advanced stage cancer patients.   Voximetry leverages intellectual property developed at the University of Wisconsin - Madison, which has a rich history of fostering successful biotechnology companies.